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In Brief
BET bromodomain inhibitors effectively
reverse cancer phenotypes but also alter
normal cellular activity. Wu et al. describe
a phosphorylated region of BRD4 that is
critical for HPV origin replication and
interacts with the HPV E2 protein.
Compounds targeting phospho-BRD4
block E2-regulated viral and cellular gene
transcription.
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Post-translational modification canmodulate protein
conformation and alter binding partner recruitment
within gene regulatory regions. Here, we report that
bromodomain-containing protein 4 (BRD4), a tran-
scription co-factor and chromatin regulator, uses
a phosphorylation-induced switch mechanism to
recruit E2 protein encoded by cancer-associated
human papillomavirus (HPV) to viral early gene
and cellularmatrixmetalloproteinase-9 (MMP-9) pro-
moters. EnhancedMMP-9 expression, induced upon
keratinocyte differentiation, occurs via BRD4-depen-
dent recruitment of active AP-1 and NF-kB to their
target sequences. This is triggered by replacement
of AP-1 family members JunB and JunD by c-Jun
and by re-localization of NF-kB from the cytoplasm
to the nucleus. In addition, BRD4 phosphorylation
is critical for E2- and origin-dependent HPV DNA
replication. A class of phospho-BRD4-targeting
compounds, distinct from the BET bromodomain
inhibitors, effectively blocks BRD4 phosphoryla-
tion-specific functions in transcription and factor
recruitment.
INTRODUCTION
Bromodomain and extraterminal (BET) family proteins are epi-
genetic readers that bind to select acetylated lysine residues
in histone and non-histone proteins to facilitate the action of
DNA-binding factors and associated co-regulators inmodulating
transcription (Wu et al., 2013; Roe et al., 2015). In humans, there
are four BET family proteins, including widely expressed bromo-
domain-containing protein 4 (BRD4), BRD3, BRD2, and testes-
and germ cell-specific BRDT (Wu and Chiang, 2007). In addition,
three alternative splicing-generated protein isoforms and a chro-
mosomal translocation-created fusion protein were described
for BRD4 (Floyd et al., 2013; Chiang, 2014). These distinct
BET proteins regulate transcription at the template commitment,Cell R
This is an open access article under the CC BY-Ninitiation, or elongation steps through recruitment of gene-spe-
cific transcription factors, the Mediator complex, or positive
transcription elongation factor b (P-TEFb) to RNA polymerase II
(Pol II)-driven promoters (Chiang, 2009).
Recent identification of BRD4 as an anti-inflammatory and
cancer therapeutic target has been facilitated by compounds
that mimic acetyl-lysine, such as JQ1 (Filippakopoulos et al.,
2010), I-BET (Nicodeme et al., 2010), and MS417 (Zhang et al.,
2012). These compounds specifically target BET bromodomains
and have stimulated broad interest in understanding BRD4-
regulated cancer-specific and drug-resistant pathways (Fong
et al., 2015; Rathert et al., 2015). There is also strong interest
in the normal cellular functions of BRD4, including intestinal
stem cell renewal and T cell development (Bolden et al., 2014),
memory formation and learning (Korb et al., 2015), and X chro-
mosome inactivation (Wu et al., 2015). Although significant prog-
ress has been made in understanding BRD4-activated path-
ways, very little is known about BRD4-inhibited transcription. It
is unclear whether BRD4 entails the same or distinct domains
and partner binding proteins to effect gene activation versus
repression.
To further define themolecular mechanisms underlying BRD4-
mediated gene activation and repression, we used the human
papillomavirus (HPV)-encoded E2 protein. E2 is a sequence-
specific transcription/replication factor (Chiang et al., 1992;
McBride, 2013) that inhibits activator protein-1 (AP-1)-driven
transcription from HPV chromatin, wherein BRD4 is required
for repression (Wu et al., 2006). Depending on the sequence
context, E2 can activate transcription in a BRD4-dependent
manner (Lee and Chiang, 2009).
Here, we report that the phosphorylation-dependent interac-
tion domain (PDID) of BRD4, previously shown to be crucial for
chromatin targeting and gene activation by the p53 tumor
suppressor protein (Wu et al., 2013), is also important for E2-
regulated transcription and chromatin contact. Remarkably,
the PDID is recognized only by E2 proteins encoded by the
oncogenic HPV-16 and HPV-18 strains that are associated
with cervical, head-and-neck, and anal cancers, not by non-
oncogenic low-risk HPV-11 and bovine papillomavirus type 1
(BPV-1). PDID-dependent inhibition of the viral promoter re-
quires E2 binding to its target site, and the same region ofeports 16, 1733–1748, August 9, 2016 ª 2016 The Author(s). 1733
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
BRD4 is needed for E2-mediated HPV origin of replication (ori)
and E2-enhanced nuclear factor kB (NF-kB)-induced matrix
metalloproteinase-9 (MMP-9) transcription. Our findings indicate
that BRD4 phosphorylation is essential for viral and cellular tran-
scription factors to reprogram gene expression pathways impli-
cated in cell fate decisions and differentiation control.
RESULTS
Identification of Two Phospho Switch-Regulated
E2-Interacting Domains in BRD4
Besides the C-terminal motif (CTM) of BRD4, which is known to
recruit P-TEFb (Bisgrove et al., 2007) and different types of E2
protein (Muller et al., 2012), we found an internal region of mouse
Brd4 (amino acid [aa] 280–580) able to interact directly with HPV-
11 E2 (11E2; Wu et al., 2006). To see whether this region repre-
sents another universal E2-interacting domain likewise used by
human BRD4, we performed a glutathione S-transferase (GST)
pull-down experiment by incubating the bacterially (Bac)-ex-
pressed FLAG-tagged human BRD4 (f:BRD4) region (aa 279–
579) with immobilized GST-tagged BPV-1 E2 (BE2), 11E2,
HPV-16 E2 (16E2), or HPV-18 E2 (18E2; Figure S1A). This internal
BRD4 region interacted with different types of E2 (Figure 1A, row
a). Further mapping pinpointed this second universal E2-inter-
acting region to a basic residue-enriched interaction domain
(BID) spanning aa 524–579 (Figure 1A, rows a–c; Figures S1B
and S1C). The region preceding BID (aa 287–530, fragment b),
when expressed in and purified from insect Sf9 cells (fragment
5), showed selective interaction only with high-risk 16E2 and
18E2, not with low-risk 11E2 and BE2 (lanes 5 and 6 versus lanes
3 and 4). In contrast, Sf9-BID (fragment 6) and Sf9-CTM (frag-
ment 10) both interacted with every type of E2 (Figure 1A). This
aa 287–530 fragment b region was previously defined as a
PDID for casein kinase II (CK2)-mediated BRD4 association
with p53 (Wu et al., 2013). To test the importance of phosphory-
lation, we treated Sf9-purified FLAG-tagged PDID (f:PDID) with
calf intestinal alkaline phosphatase (CIP) or Bac-purified f:PDID
with CK2 that, respectively, abolished (Figure 1B, top panel) or
restored (Figure 1B, bottom panel) PDID interaction with 16E2
and 18E2. These data show phosphorylation of PDID is crucial
for selective BRD4 association with high-risk E2.
To determine whether phosphorylation at the N-terminal clus-
ter of CK2 phosphorylation sites (NPS) in PDID confers selective
E2 association, we deleted bromodomain II (DBD2) from PDID
and used CK2-phosphorylated Bac-purified PDIDDBD2 (named
phospho-NPS, or pNPS) for the GST pull-down. Although GST-
CTM and GST-BID interacted with every type of E2 as expected,
pNPS only interacted with 16E2 and 18E2 (Figure 1C). Alanine
substitution of serine (or threonine) at each of the eight CK2
phosphorylation sites in Sf9-purified PDID showed that S488,
S492, S494, S498, and S499 in NPS are important for phos-
pho-PDID interaction with 16E2, 18E2, p53, and BID; T500 and
S503 are also required for BID interaction (Figure 1D). Because
NPS phosphorylation is necessary for its intra-molecular contact
with BID (Wu et al., 2013), accessibility of BID for universal
E2 interaction is likely regulated by the phosphorylation status
of NPS (Figure 1E). A protein fragment containing both PDID
and BID with unphosphorylated NPS could interact with every1734 Cell Reports 16, 1733–1748, August 9, 2016type of E2, whereas the same fragment when phosphorylated
showed select contact only with high-risk 16E2 and 18E2 (Fig-
ure 1A, fragment a versus fragment 4). This was validated in vivo
by GST pull-down in transfected human 293 cells (Figure S1D).
Phosphorylation at the C-terminal cluster of CK2 phosphoryla-
tion sites (CPS) residing in aa 598–785 of BRD4 could not confer
E2 association (Figure 1A, fragment 7; Figure S1E). Furthermore,
the phospho-mimic 8E mutant of Bac-purified f:PDID failed to
interact with 16E2, 18E2, p53, and BID (Figure S1F). These
results strongly indicate that context-dependent CK2 phosphor-
ylation, not purely charge distribution, is critical for select E2
contact with BRD4.
The existence of a CTM-independent E2-interacting region in
BRD4 was examined in vivo by co-immunoprecipitation (coIP) in
293 cells expressing full-length (FL) or CTM-deleted (DCTM)
f:BRD4 and GST-tagged 11E2, 16E2, or 18E2. While endoge-
nous p53 interacts equally well with FL and DCTM BRD4 in a
CTM-independent manner (Wu et al., 2013) and DCTM is unable
to interact with 11E2 due to masking of BID in vivo by phospho-
PDID, DCTM retains a significant level of 16E2 and 18E2 interac-
tion (Figure 1F). Unmasking of BID for 11E2 interaction could be
demonstrated in vitro using CIP-treated DCTM protein, with or
without additional deletion of other non-E2-interacting domains
(Figure S1G, lane 3 versus lane 7). The CTM-dependent 11E2 as-
sociation and DCTM-permissible 16E2 and 18E2 interaction
were further illustrated by live-cell imaging using a bimolecular
fluorescence complementation (BiFC) assay (Wu et al., 2013).
Co-expression of Venus N terminus (VN)-linked E2 and Venus
C terminus (VC)-conjugated BRD4 in HPV-positive HeLa cells
(Figure 1G) and HPV-negative C-33A cells (Figure 1H) restored
fluorescence from the split Venus fluorophore.
Phospho-PDID Contact Residues in E2 Residing at the
C-Terminal End of Its DNA Recognition Helix
To identify the region of E2 contacting the identified BID and
phospho-PDID in BRD4, we performed GST pull-down experi-
ments by incubating phosphorylated Sf9-purified f:PDID, non-
phosphorylated Bac-purified f:PDID (negative control), Bac-puri-
fied FLAG-tagged BID (f:BID), and Bac-purified FLAG-tagged
CTM (f:CTM; positive control), each with the N-terminal, C-termi-
nal, or hinge plus C (HC) region of GST-11E2 or GST-18E2 (Fig-
ure S2A). While f:CTM interacts with the E2 N-terminal regulatory
domain aspreviously reported (Lee andChiang, 2009), f:BID inter-
acts specifically with the C-terminal DNA binding and dimeriza-
tion (DBD) domain of 11E2 and 18E2 and only Sf9-purified
f:PDID interacts with the 18E2 C terminus (Figure 2A). This bipar-
tite interaction between E2 and BRD4was further examined using
Sf9-purified f:BRD4 FL and DCTM (Figure 2B). The 18E2 N termi-
nus and 11E2N terminus interactedwith FL but notDCTM,with or
without CIP treatment (lanes 2 and 4). The 18E2 C terminus, but
not the 11E2C terminus, interactedwith both FL andDCTM (lanes
3 and 5, first and third rows). Upon CIP treatment, the 11E2 C ter-
minus interacted with both FL and DCTM (lane 5). These in vitro
interaction assays demonstrate that BRD4 uses the CTM as a
common E2 N terminus-interacting domain and phospho-PDID
for direct contact only with high-risk E2 (Figure 2C), not with
low-risk E2 (Figure 2D). Normally masked BID in FL and DCTM
BRD4 could be unmasked for universal E2 interaction when
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Figure 1. BRD4 Uses BID for Common E2 Interaction and Phospho-PDID for Select High-Risk E2 Contact
(A) Domain mapping of BRD4 for E2 interaction by GST pull-down.
(B) CIP treatment of Sf9-purified phospho-PDID abolishes its interaction with 16E2 and 18E2, whereas CK2 treatment of Bac-purified PDID confers its interaction
with 16E2 and 18E2.
(C) BID and CTM each interact with different types of E2, and pNPS interacts specifically with high-risk 16E2 and 18E2.
(D) Substitution of S488, S492, S494, S498, and S499, individually, to alanine reduces the respective Sf9-purified PDID interactionwith 16E2, 18E2, p53, and BID,
with T500 and S503 additionally required for BID interaction.
(E) Model for phosphorylation-regulated E2 contact with PDID and BID.
(F) Deletion of CTM abolishes BRD4 interaction with 11E2 but only partially reduces BRD4 interaction with 16E2 and 18E2 in transfected 293 cells. The asterisk
indicates a cross-reacting species.
(G) BiFC live-cell imaging in transfected HeLa cells.
(H) Counting BiFC-positive cell numbers in transfected C-33A.
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NPS is dephosphorylated, highlighting the discovery of a selec-
tive and common E2-interaction domain in internal BRD4 regu-
lated by phosphorylation and dephosphorylation.
To unravel the molecular basis for phospho-PDID contact with
select E2, we inspected the DBD sequences of 16E2, 18E2, and
11E2, in alignment with other phospho-PDID-interacting do-
mains, such as BID and the p53 C-terminal regulatory domain
(Figure S2B; Wu et al., 2013). These alignments revealed two
conserved basic residues in 16E2 (K306 and K307) and 18E2
(R307 and K308) that are replaced by non-basic residues in
11E2 (N304 and D305; Figure 2E, two red arrows). Mutation of
these two basic residues in 16E2 and 18E2 to ND, as found in
11E2, abolished phospho-PDID interaction, whereas substitut-
ing ND in 11E2 with KK, as found in 16E2, led to 11E2 interaction
with phospho-PDID at a level comparable to that seen with wild-
type 16E2 and 18E2 (Figure 2F). These two amino acid substitu-
tions in FL E2, with levels of expression similar to those of the
wild-type proteins (Figure S2C), were also examined for their
interaction in vivo with FL and DCTM BRD4 by BiFC live-cell im-
aging. 16E2-ND and 18E2-ND mutants showed the expected
interaction with FL but not DCTM, reflecting a strict CTM-depen-
dent interaction due to the loss of their internal phospho-PDID
contact residues (Figure 2G). In contrast, the 11E2-KK mutant
acquires a unique interaction with DCTM. These data demon-
strate that the two basic residues present in high-risk 16E2
and 18E2 are crucial determinants for select contact with
BRD4 phospho-PDID.
These two residues are situated in the C-terminal end of the
DNA recognition helix in the E2 DBD, which features a dimeric
barrel possessing eight anti-parallel b strands and four a helices
(Figure S2D), with a1 of each monomer contacting the major
groove (Figure S2E) at specific bases and phosphates (Fig-
ure S2F). We mutated each of the three conserved basic resi-
dues (K299, R302, and R304) in the 16E2 a1 DNA recognition
helix (Figure 2E) to leucine. We then examined, along with
the K306N and K307D selectivity-determining mutants, their
ability to interact with phospho-PDID by GST pull-down. Clearly,
K306 is more important than K307 for interacting with phospho-
PDID. R302, but not the base-contacting K299 and R304 resi-
dues, is also crucial for phospho-PDID interaction (Figure 2H).
These three phospho-PDID-interacting residues in 16E2 (K306,
K307, and R302) are adjacent within a solvent-accessible area
on the opposite side of the DNA-contacting surface based on
the locations of the corresponding residues (R307, K308, and
R303) in the available 18E2 DBD/DNA structure (Figure 2I; Fig-
ure S2G; Kim et al., 2000; McBride, 2013).Figure 2. Identification of Phospho-PDID Contact Residues in E2 to th
(A) GST pull-down shows CTM BRD4 interacts with the 11E2 N terminus (N) a
terminus (C).
(B) CIP treatment releases phospho-PDID-masked BID in FL and DCTM for 11E
(C) Model for phosphorylation-switchable bipartite BRD4 interaction with high-ri
(D) Model for phosphorylation-regulated mono- or bipartite BRD4 interaction wit
(E) Amino acid sequence alignment of 16E2, 18E2, and 11E2 DBDs, with import
(F) Switch of two amino acids at the C-terminal end of the DNA recognition helix be
PDID of BRD4.
(G) BiFC imaging in HeLa cells showing substitutions of two contact selectivity r
(H) 16E2 interaction with phospho-PDID is reduced significantly by mutation at K
(I) Model for 18E2 DBD binding to DNA (E2BS) showing surface-exposed R303,Phospho-PDID-Targeting Compounds Disrupt Select
E2-BRD4 Interactions
Given the importance of phosphorylation in regulating intra-mo-
lecular PDID-BID contact that, in turn, regulates inter-molecular
BRD4-E2 interaction, we tested whether our previously isolated
phospho-PDID-targeting peptoid compounds, DC-1 and DC-2
(Figures S3A–S3C; Cai et al., 2011), could disrupt phospho-
PDID association with 16E2, 18E2, and BID. We found that
DC-1 and DC-2 both effectively blocked Sf9-purified f:PDID
interaction with 16E2, 18E2, and BID in a dose-dependent
manner. In contrast, a randomized control peptoid (Figure S3D)
and the BET bromodomain-specific inhibitor JQ1(+) had no ef-
fect on these binary interactions (Figure 3A). The disruption by
DC-1 and DC-2 was specific to phospho-PDID-mediated inter-
action, because CTM-driven association with 16E2 and 18E2
was not affected by the addition of these two compounds (Fig-
ure 3B). Consistent with the observation that phospho-PDID
bound 16E2 most strongly, followed by BID and then 18E2 (Fig-
ure S3E), higher concentrations of DC-1 and DC-2 were needed
to disrupt phospho-PDID interaction with 16E2 than with 18E2
(Figures 3A and 3C).
To examine whether compounds that target phospho-PDID
could disrupt E2 interaction with intact BRD4 protein, we
analyzed the ability of the more effective DC-1 compound to
inhibit the CTM-independent interaction between the Sf9-puri-
fied short isoform of BRD4 (BRD4-S; aa 1–722; Wu et al.,
2013) and 16E2, 18E2, and 11E2. We observed that 20 mM
of DC-1 (lane 4) inhibited 18E2 but not 16E2 interaction with
BRD4-S (Figure 3D), consistent with the inhibitory dosage
seen with phospho-PDID and 18E2 interaction (Figure 3A,
lane 4). No inhibition was seen when the DC-1 concentration
was greater than 20 mM (lanes 5 and 6). This result is likely
due to a switch of E2 interaction with BRD4-S from phos-
pho-PDID to BID, thereby disguising the loss of phospho-
PDID and 18E2 contact, as independently revealed by un-
masking of BID upon DC-1-disrupted phospho-PDID and
BID interaction now available for 11E2 interaction (Figure 3D,
last row).
When inhibition by DC-1 was repeated with the long (FL) iso-
form of BRD4 (aa 1–1362), similar patterns of dose-dependent
inhibition were observed, except that CTM dependence was
clearly seen in 11E2 interaction with BRD4 (Figure 3E, last row,
versus Figure 3D, last row, lanes 1–4). Evidently, CTM-depen-
dent BRD4 interaction with the N-terminal domain of E2 could
be strengthened by a second domain interaction between the
phospho-PDID and the C-terminal domain of high-risk E2 ore C-Terminal End of Its DNA Recognition Helix
nd 18E2 N, whereas BID and phospho-PDID both interact with the 18E2 C
2 C interaction but does not alter BRD4 interaction with 18E2.
sk E2.
h low-risk E2.
ant residues for phospho-PDID binding underlined or arrowed in red.
tween high-risk and low-risk E2 alters their interaction specificity with phospho-
esidues in FL E2 change their binding specificity with FL and DCTM BRD4.
306 and partially by substitution of K307 and R302 residues.
R307, and K308 critical for BRD4 interaction.
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Figure 3. Phospho-PDID-Targeting Compounds Disrupt Select E2-BRD4 Interaction
(A) Inhibition of phospho-PDID interaction with 16E2, 18E2, and BID by increasing doses of DC-1 and DC-2 but not DC-control peptoid and JQ1(+).
(B) DC-1 and DC-2 cannot disrupt CTM interaction with 16E2 and 18E2.
(C) Kd and IC50 of DC-1 and DC-2 for phospho-PDID interaction with 16E2, 18E2, and BID.
(D) Titration of DC-1 for disrupting CTM-lacking BRD4-S interaction with 16E2 and 18E2 or unmasking BID in BRD4-S for 11E2 interaction.
(E) Titration of DC-1 for disrupting CTM-containing FL BRD4 interaction with 16E2 and 18E2 or unmasking BID in BRD4 for 11E2 interaction.
(F) Comparison of DC-1 and JQ1(+) concentrations needed for blocking BRD4 binding to acetylated (Ac-) chromatin.
(G) Model for low-concentration DC-1 blocking of 18E2 recruitment and high-concentration DC-1-induced conformational change masking BD2 binding to Ac-
chromatin.between the DC-1-unmasked BID and the C-terminal domain of
E2, particularly 11E2 (Figure 3E, lanes 1–4 versus lanes 5–7).
To investigate the direct involvement of the unmasked BID with
E2, we removed BID from FL BRD4 and observed no enhanced1738 Cell Reports 16, 1733–1748, August 9, 2016E2 interaction with BRD4DBID at high DC-1 concentrations
(Figure S3F).
Disruption of phospho-PDID and BID interaction also re-
sults in an intra-molecular contact switch from NPS-BID to
NPS-BD2 (Wu et al., 2013). Therefore, we predicted that DC-1
would block BRD4 binding to acetylated chromatin once BD2,
which is capable of binding to acetyl-lysine in nucleosomal
histones, is blocked by the unleashed NPS from its BID an-
chor. DC-1, but not the control peptoid, blocked BRD4 bind-
ing to acetylated chromatin at 330 and 500 mM (Figure 3F,
lanes 1–8), concentrations greater than the 27 mM half
maximal inhibitory concentration (IC50) measured for DC-1-
mediated disruption of phospho-PDID-BID interaction (Fig-
ure 3C). This inhibition, however, was 1,000-fold less effec-
tive as that achieved by active JQ1(+) relative to its inactive
stereoisomer JQ1() (Figure 3F). These data indicate that inhi-
bition of BRD4 binding to acetylated chromatin by an indirect
mechanism via DC-1-induced NPS masking of BD2 is signifi-
cantly weaker than direct blocking of bromodomain access
to chromatin by JQ1. Higher concentrations of DC-1 are prob-
ably needed to block not only BD2-mediated chromatin asso-
ciation but also bromodomain I (BD1)-synergized BD2 binding
to acetylated chromatin (Wu et al., 2013). Nevertheless, phos-
pho-PDID-targeting compounds provide a unique window of
opportunity at low concentrations to block factor (e.g., 18E2)
association with phospho-PDID without inhibiting BRD4 bind-
ing to its chromatin targets, even though at high concentra-
tions they can also inhibit bromodomain binding to acetylated
chromatin (Figure 3G).
Bipartite Contact Crucial for BRD4-Mediated E2
Repression of HPV Early Promoter
To define the role of the three BRD4 E2-interacting domains in
E2-regulated promoter function, we analyzed integrated HPV-
18 long control region (LCR)-driven luciferase reporter activity
in three human cervical cancer-derived C-33A cell lines stably
expressing FLAG-hemagglutinin (HA)-tagged 16E2, BE2, or vec-
tor alone (Figure 4A; Smith et al., 2010). Expression of either E2
protein significantly suppresses HPV early promoter-containing
LCR activity (Figure 4B, solid bars), consistent with E2 acting pri-
marily as a transcriptional repressor inhibiting HPV early pro-
moter activity (Hou et al., 2000; Wu et al., 2006; Smith et al.,
2010).
Alleviation of E2 repression could be partly achieved by adding
JQ1(+), but not JQ1(), to the culture medium (Figure 4B; Fig-
ure S4A) or by small interfering RNA (siRNA) knockdown of
endogenous BRD4 (Figure 4C). These data confirm that BRD4
is a cellular co-repressor for E2-inhibited HPV transcription
(Wu et al., 2006; Smith et al., 2010). Involvement of the three
E2-interacting domains in BRD4-mediated E2 repression was
then addressed by creating 15 C-33A/18LCR-derived stable
cell lines expressing FL triple FLAG-tagged BRD4 (3f:BRD4),
domain-specific deletion of each E2-interacting region (DNPS,
DBID, and DCTM), or control vector () in each of the three re-
porter lines concurrently expressing 16E2, BE2, or vector alone
(Figure 4D). Expression of exogenous BRD4 derivatives is com-
parable in these lines (Figure 4E, a-FLAG antibody). The total
amount of BRD4 in each line was equivalent to the level of
endogenous BRD4 found in vector control cells except in BE2-
expressing cells, where exogenous BRD4 derivatives, particu-
larly DBID, are higher than the endogenous protein (Figure S4B,
a-BRD4 N-terminal antibody).Knockdown of endogenous BRD4 in 16E2-expressing cells
led to derepression of LCR-driven reporter activity, which was
rescued only by ectopic expression of FL BRD4 but not by any
of the domain-specific deletion derivatives (Figure 4F). These
data show that both NPS and CTM of BRD4 are required for
16E2-mediated repression of HPV early promoter. Because
DBID is a chromatin binding-defective mutant (Wu et al., 2013),
ectopic expression of DBID was unable to compensate for the
loss of endogenous BRD4 function. In contrast, NPS is dispens-
able for ectopic BRD4 to confer BE2 repression in endogenous
BRD4-knockdown BE2 cells (Figure 4G), providing functional
validation of unique NPS contact with high-risk but not low-
risk E2.
We also monitored E2 binding by chromatin immunoprecipita-
tion (ChIP) to the promoter-proximal #3 and #4 E2-binding sites
(E2BSs) in the LCR, which are critical for E2-mediated repression
of HPV early promoter (Hou et al., 2000; Wu et al., 2006). These
experiments revealed that E2 binding to these two cognate sites
accounted for the ability of ectopic FL BRD4 to both rescue E2-
mediated repression in endogenous BRD4-knockdown 16E2
cells (Figure 4H, left) and restore E2 repression by ectopic FL
and DNPS in small interfering BDR4 (siBRD4)-treated BE2 cells
(Figure 4I, left). Occupancy of BRD4 derivatives at the #3 and
#4 E2BSs is consistent with the described chromatin-binding
property of these BRD4 mutants (Wu et al., 2013) in that DNPS
exhibits enhanced chromatin binding due to deletion of the bro-
modomain-masking NPS, DBID is defective in chromatin bind-
ing, and DCTM has no effect on BRD4 binding to chromatin (Fig-
ures 4H and 4I, right). These data highlight the universal BRD4
domain-implicated regulation applicable not only to transcrip-
tional activation, as previously described for p53 (Wu et al.,
2013), but also to transcriptional repression, as illustrated here
for HPV E2.
Phosphorylation of BRD4 NPS Is Critical for High-Risk
E2-Mediated HPV Promoter Repression and Viral Origin
Replication
To demonstrate involvement of phosphorylation at the NPS of
BRD4 in E2-inhibited HPV promoter activity, we established
another eight C-33A/18LCR-derived stable cell lines expressing
different alanine-substituted serine or threonine mutants (a–c
and 7A) of BRD4. The levels of total BRD4 were comparable in
reporter lines concurrently expressing 16E2 or BE2 (Figure S4C,
a-BRD4 N-terminal antibody) that showed impaired phosphory-
lation at specific residues as described (Figure 5A; Wu et al.,
2013). None of these mutants were able to substitute for
wild-type BRD4 in conferring repression in endogenous BRD4-
knockdown 16E2 cells (Figure 5B). In contrast, all phosphoryla-
tion-defective BRD4 mutants retained co-repressor activity as
effective as wild-type BRD4 in endogenous BRD4-knockdown
BE2 cells (Figure 5C), confirming that NPS phosphorylation is
critical for high-risk but not low-risk E2-mediated repression of
HPV promoter activity.
To investigate whether the phosphorylation requirement of
BRD4 could also be observed in HPV-positive cervical cancer
cells, we analyzed endogenous HPV-18 promoter activity upon
BRD4 knockdown in HeLa cells that also express exogenous
HPV-16 E6 (16E6) andHPV-16 E7 (16E7) oncoproteins to bypassCell Reports 16, 1733–1748, August 9, 2016 1739
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Figure 4. NPS of BRD4 Is Specifically Required for High-Risk, but Not Low-Risk, E2-Mediated Inhibition of HPV Early Promoter Activity
(A) Three C-33A-derived HPV-18 LCR-driven luciferase reporter lines expressing 16E2, BE2, or vector alone.
(B) Inhibition of 18LCR-containing HPV early promoter activity in 16E2- and BE2-expressing cells is partially alleviated by JQ1(+), but not JQ1(), treatment.
(C) Knockdown of BRD4 alleviates 16E2 and BE2 repression of HPV early promoter activity in E2-containing reporter lines.
(D) Generation of 15 stable luciferase reporter cell lines expressing ectopic or domain-specific deletion of BRD4 in three parental reporter E2 lines.
(E) Levels of ectopic BRD4 expression in 15 reporter lines.
(F) Only ectopically expressed FL, not domain-deleted BRD4, rescues 16E2 repression in endogenous BRD4-knockdown reporter lines.
(G) Ectopically expressed FL and DNPS rescue BE2 repression in endogenous BRD4-knockdown reporter lines.
(H and I) ChIP assay showing E2 and BRD4 binding to promoter-proximal E2BS in (H) 16E2 and (I) BE2 reporter lines.
Error bars, SD (n = 3–6 in B, C, F, and G; n = 3 in H and I).
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Figure 5. Phosphorylation of BRD4 Is Critical for High-Risk E2-Mediated HPV Promoter Repression and Viral Origin Replication
(A) Immunoblotting of BRD4 wild-type (WT), DNPS, and alanine-substituted NPS-phosphorylation-site mutants in clusters (a–c) or in combination (7A).
(B) Ectopically expressed WT BRD4, but not NPS-phosphorylation-site mutants, rescues 16E2-mediated repression of HPV-18 promoter activity in endogenous
BRD4-knockdown reporter lines.
(C) All ectopically expressed BRD4 NPS-phosphorylation-site mutants rescue BE2-repressed HPV-18 promoter activity in endogenous BRD4-knockdown re-
porter lines.
(D) Knockdown of endogenous BRD4 alleviates 16E2-repressed endogenousHPV-18 promoter activity, as shown by enhanced 18E6 RNA levels (left) and protein
levels (right), in 16E2-expressing HeLa/16E6/16E7 cells.
(E) PP2A activator PTZ elevates the 18E6 RNA level (left) and reduces BRD4 phosphorylation (right) in 16E2-containing but not in E2-absent () cells.
(F) Ectopic expression ofWTBRD4 but not 7Amutant promotes E1- and E2-dependent ori replication (left) and rescues loss of ori replication (right) in endogenous
BRD4-knockdown C-33A cells. HPV-16 E1, Myc:E2, and an HPV-16 ori plasmid were co-transfected into C-33A cells with or without BRD4 knockdown. The
insert shows comparable expression levels of WT 3f:BRD4 and 7A mutant expressed in transfected C-33A cells.
(G) Confocal cell imaging showing ectopic expression of WT BRD4 but not 7Amutant enhances ori-dependent Myc:E2/BRD4 foci formation in transfected C-33A
cells. Cells with >10 Myc:E2/3f:BRD4-costained nuclear foci were quantitated, with the percentage of positive staining shown in a bar graph. Scale bar, 5 mm.
Error bars, SD (n = 4–6 in B–E; n = 3 in F and G).stable 16E2 expression-induced cell-cycle arrest and senes-
cence (Smith et al., 2010). Knockdown of BRD4 alleviated
16E2-mediated repression of endogenous HPV-18 E6 (18E6)
RNA and protein (Figure 5D). Loss of 16E2 inhibition in BRD4-knockdown cells was rescued by exogenous expression of
wild-type BRD4, but not by the 7A phosphorylation-defective
mutant (Figure S4D). Alleviation of 16E2-mediated inhibition of
HPV-18 promoter activity could also be achieved by addingCell Reports 16, 1733–1748, August 9, 2016 1741
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Figure 6. E2-Upregulated MMP-9 Expression in Differentiating Keratinocytes Depends Specifically on BRD4-L, but Not BRD4-S, BRD2,
and BRD3
(A) Expression of 11E2 or 18E2 in Ker-CT-derived stable lines does not change the level of Involucrin upon serum- and calcium-induced differentiation. Asterisk
indicates a non-specific band detected by a-FLAG antibody.
(B) Expression of differentiation-induced MMP-9, but not Involucrin, is enhanced by 18E2.
(C) In-gel zymography assay showing gelatinase activity of secreted MMP-9 in 18E2-expressing Ker-CT cells is higher than that secreted from 11E2 and vector
cells.
(D) Cell migration assay showing conditioned medium collected from 18E2-expressing Ker-CT cells enhances HT1080 cell migration.
(E) Proliferation assay showing JQ1(+) inhibits cell growth of the three Ker-CT lines with or without E2 expression. UNT, untreated.
(F) Scheme of JQ1 treatment.
(legend continued on next page)
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the pharmacological stimulator phenothiazine (PTZ) of protein
phosphatase 2A (PP2A) that dephosphorylates BRD4 in cells
(Figure 5E; Shu et al., 2016).
Because E2 is also important for HPV ori function (Chiang
et al., 1992) and BRD4-E2 interaction was shown to be critical
for HPV-16 ori replication in C-33A cells (Wang et al., 2013),
we wondered whether phosphorylation of BRD4 plays an essen-
tial role in HPV-16 ori replication. Using an E1- and E2-depen-
dent transient replication assay (Chiang et al., 1992) performed
in C-33A cells transfected with HPV-16 E1, Myc-tagged 16E2
(Myc:E2), and an HPV-16 ori-containing plasmid with or without
exogenous 3f:BRD4 expression, we found E1- and E2-potenti-
ated ori replication could be enhanced by wild-type BRD4 but
not the 7A mutant (Figure 5F, left). In BRD4-knockdown cells,
loss of E1- and E2-dependent ori replication could be effectively
rescued by wild-type BRD4 but not the 7A mutant (Figure 5F,
right). Consistent with this finding, cell imaging showed that
formation of ori-dependent Myc:E2/3f:BRD4 foci in transfected
C-33A cells was significantly enhanced by wild-type but not
the 7A mutant (Figure 5G). These data demonstrate a critical
role of BRD4 phosphorylation in both HPV transcription and
ori-dependent replication control.
E2-Upregulated MMP-9 Expression in Differentiating
Keratinocytes Depends on a Specific BRD4 Isoform, but
Not BRD2 and BRD3
Because keratinocytes are the natural host for HPV infection,
we used immortalized but non-transformed human keratino-
cytes (Ker) immortalized by CDK4 (C) and telomerase (T)
expression (Ker-CT) to establish stable cell lines expressing
low-risk 11E2, high-risk 18E2, or vector alone for analyzing
cellular promoters co-regulated by E2 and phospho-BRD4.
When differentiation was induced in these keratinocyte lines
by addition of serum and calcium to serum-free keratinocyte
growth medium, as shown by enhanced expression of Involu-
crin (Figure 6A), MMP-9 RNA was upregulated weakly by
11E2 and significantly by 18E2 in a differentiation-dependent
manner (Figure 6B). In contrast, proliferation-related genes,
such as ITGB4, K14, c-Myc, KLF4, RPL32, and RPL13A, were
downregulated upon differentiation. 18E2-stimulated MMP-9
expression could be detected in the secreted or conditioned
medium, which showed active MMP-9 gelatinase activity (and
that of serum-carried MMP-2) in degrading the extracellular
matrix component gelatin in an in-gel enzymatic activity assay
(Figure 6C) and in stimulating HT1080 human fibrosarcoma
cell migration (Figure 6D).
The involvement of BRD4 in keratinocyte proliferation is not E2
dependent, because growth of these three Ker-CT lines was
similarly inhibited by addition of JQ1(+) (Figure 6E). This result
is consistent with a lack of significant changes in proliferation-
related gene expression (Figure 6B, first three columns). To
determine whether E2-upregulated MMP-9 expression in differ-
entiation-induced Ker-CT cells is likewise controlled by BRD4,(G) JQ1(+) suppresses the differentiation-induced MMP-9 RNA level enhanced b
(H) Knockdown of BRD4-L, but not BRD4-S, BRD2, or BRD3, suppresses the di
(I) JQ1(+) suppresses the differentiation-induced Involucrin RNA level independe
(J) Knockdown of BRD4-L, BRD2, or BRD3, but not BRD4-S, suppresses the difas had been found in the E2-regulated HPV promoter, we added
JQ1 (100 nM) 24 hr before serum- and calcium-induced differen-
tiation with replenished JQ1 (Figure 6F). JQ1(+) significantly in-
hibited differentiation-induced MMP-9 gene expression in both
basal (white bar) and E2-stimulated (gray and black bars) path-
ways (Figure 6G). Choosing a low JQ1 concentration with pro-
longed treatment allowed us to follow the extent of keratinocyte
differentiation by monitoring protein markers, such as Involucrin,
for differentiation, which could take up to 96 hr depending on the
culturing condition. Treating Ker-CT cells with JQ1 for only 2 hr,
instead of 24 hr, before differentiation showed no difference in in-
hibiting MMP-9 RNA expression (Figure S4E).
To define which BET protein is involved in E2-dependent
MMP-9 activation, we performed siRNA knockdown for long-
form-specific BRD4 (BRD4-L), BRD4-S, and both long-form
and short-form (Pan) BRD4, as well as BRD2 and BRD3. Only
knockdown of BRD4-L, as seen in Pan and long-form siRNA,
suppressed 18E2-dependent activation of MMP-9 (Figure 6H).
This phenocopied JQ1-inhibited MMP-9 expression (Figure 6G)
and indicated that FL BRD4, rather than other BET family pro-
teins, was involved in high-risk E2-upregulated MMP-9 gene
transcription. In contrast, differentiation-induced Involucrin ex-
pression inhibited by JQ1(+) was E2 independent (Figure 6I)
and redundantly controlled by BRD4-L, BRD3, and BRD2 (Fig-
ure 6J), indicating that differentiation-induced genes could be
either uniquely (e.g.,MMP-9) or commonly (e.g., Involucrin) regu-
lated by different BET family proteins. Only BRD4-L, not BRD4-
S, BRD3, or BRD2, was also uniquely required for E2-inhibited
HPV early promoter activity when eachBET protein was knocked
down by siRNA (Figure S4F). Enhancement of the MMP-9 RNA
level upon knockdown of BRD2 or BRD3, unlike that seen with
Involucrin RNA, indicates that BET proteins have regulatory
properties that are gene specific and context dependent.
MMP-9Promoter Activity Is Upregulated by BRD4 pNPS-
Potentiated E2 Function and NF-kB Recruitment along
with a Switch of AP-1 Family Members
To define the molecular mechanism of BRD4 and E2 in MMP-9
gene activation and the role of pNPS in high-risk E2-specific
regulation, we analyzed the endogenous MMP-9 RNA level
in C-33A cells co-transfected with expression plasmids for
different types of E2 and either FL 3f:BRD4 or DNPS 3f:BRD4.
While ectopic FL and DNPS 3f:BRD4 stimulated BE2- and
11E2-enhanced MMP-9 expression equally well, only FL, not
DNPS, potentiated the 16E2- and 18E2-upregulated MMP-9
RNA level (Figure 7A). These data indicate that NPS in BRD4 is
essential for high-risk E2-enhanced MMP-9 gene transcription.
When 7A mutant, which shows E2 interaction comparable to
that of wild-type BRD4 (Figure S5A), was used, potentiation of
16E2, 18E2, and the 11E2-KK mutant that bestows upon 11E2
the ability to interact with pNPS was no longer observed (Fig-
ure S5B), substantiating the importance of NPS phosphorylation
residues in BRD4-potentiated E2 activation.y E2 expression.
fferentiation-induced MMP-9 RNA level in different Ker-CT-derived lines.
nt of E2 expression.
ferentiation-induced Involucrin RNA level independent of E2 expression.
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Figure 7. MMP-9 Promoter Activity Is Upregulated by BRD4 pNPS-Potentiated E2 Function and NF-kB Recruitment Together with Switch of
AP-1 Family Members
(A) DNPS in BRD4 is essential forMMP-9 gene transcription upregulated by high-risk 16E2 and 18E2 but not low-risk 11E2 and BE2 in transfected C-33A cells.
Both 18E2 and 11E2 used here are codon optimized.
(legend continued on next page)
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The requirement of NPS for endogenous BRD4-potentiated
high-risk E2 activation was then examined in three stable Ker-
CT-derived lines treated with pNPS-targeting DC-1 or control
peptoid. EnhancedMMP-9 expression by 18E2 in differentiating
keratinocytes was reduced by DC-1 (Figure 7B) without affecting
E2-independent Involucrin RNA expression (Figure S5C). This
was independently confirmed by treating differentiating cells
with the CK2 inhibitor 4,5,6,7-tetrabromobenzotriazole (TBB),
which abolished 18E2 activation upon reduction of BRD4 phos-
phorylation (Figure 7C). Thus, pNPS of BRD4 is specifically
required for high-risk E2-potentiated MMP-9 activation.
Because an E2BS situated in the MMP-9 promoter-proximal
region also containing one NF-kB and three AP-1 sites (Fig-
ure 7D, top drawing) is known to regulate MMP-9 expression
(Akg€ul et al., 2011), we performed ChIP in these three Ker-CT
lines to analyze whether BRD4 is implicated in the recruitment
of E2, NF-kB, and AP-1 to their cognate sites in regulating
MMP-9 gene transcription. In proliferating keratinocytes, binding
of E2was detected at its cognate site not only in region 2 but also
in E2BS-devoid regions 1, 3, and 4 (Figure 7D, middle). In differ-
entiating keratinocytes, E2 binding was confined to regions 2
and 4, with some 18E2 occupancy additionally found in region
3. This binding profile suggests that E2-regulated MMP-9
expression involves both direct binding to its cognate site and in-
direct association with AP-1 and NF-kB. Differentiation-induced
factor switches of AP-1 and NF-kB re-localization (described
later) likely elicit changes of E2 recruitment to non-E2BS regions.
For comparison, binding of BRD4 in proliferating keratinocytes,
initially limited to regions 1, 3, and 4 in the absence of E2, was
further detected at region 2 in the presence of 11E2. Strikingly,
BRD4 occupancy was dramatically enhanced by 18E2 in all up-
stream regions, in contrast to the gradually diminishing binding
pattern in differentiating keratinocytes starting at region 3 in
the absence of E2 or region 2 in the presence of E2 and extend-
ing to the downstream coding region when MMP-9 gene tran-
scription was induced by differentiation (Figure 7D, bottom).
To examine whether differential binding of E2 and BRD4 in
proliferating and differentiating states was attributed to pNPS-
specific recruitment of high-risk E2, we added DC-1 and found
that enhanced recruitment of 18E2 to its cognate E2BS in region
2 in proliferating but not differentiating keratinocytes was
reduced by DC-1 to the same level occupied by 11E2 (Figure 7E,
left). E2 recruitment to the proximal AP-1 site in region 4 in both
cell states was unaffected by DC-1 (Figure 7E, right), suggesting
that pNPS of BRD4 is critical for enhancing the additional level of
18E2 (versus 11E2) occupancy to its target DNA sequence but is(B) pNPS-targeting DC-1 but not its control peptoid abolishes the 18E2-potentia
(C) CK2 inhibitor TBB abolishes the 18E2-potentiated MMP-9 RNA level in differ
(D) ChIP assay monitoring E2 and BRD4 occupancy of the MMP-9 promoter-pro
(E and F) ChIP assays monitoring (E) E2 binding to region 2 (E2BS) and region 4 (p
proximal region in DC-1-treated or control peptoid-treated Ker-CT-derived kerat
(G) ChIP assay monitoring JunB, JunD, c-Jun, and p65 binding to regions 1–4 of th
derived keratinocytes.
(H) ChIP assay monitoring p65 binding to region 3 of the MMP-9 promoter-prox
nocytes in the differentiation-induced state.
(I) MMP-9 RNA level in different Ker-CT-derived cells untreated or treated with B
(J) Model for combinatorial MMP-9 promoter regulation by BRD4-dependent E2
Error bars, SD (n = 3 in A–I).nonessential for indirect recruitment of E2 to other transcription
factor-binding sites. Likewise, the extra level of 18E2-enhanced
BRD4 recruitment was reduced by DC-1, which does not affect
11E2-recruited BRD4, in differentiating keratinocytes (Figure 7F)
and proliferating cells (Figure S5D). Addition of JQ1(+) but not
JQ1() abolished BRD4 and E2 binding to all MMP-9 pro-
moter-proximal and coding regions, irrespective of cell status
(Figures S5E and S5F). Our data suggest a general role of
BRD4 in recruiting and stabilizing E2 binding to the MMP-9
gene locus and a unique role of pNPS in potentiating BRD4-
mediated high-risk E2 function.
When recruitment of AP-1 and NF-kB toMMP-9was analyzed
by promoter occupancy of Jun family proteins and p65, respec-
tively, we found that robust binding of JunB and JunD to AP-1
sites in regions 1, 3, and 4 in proliferating keratinocytes was
significantly reduced upon differentiation in control and 11E2-
expressing cells (Figure 7G). Binding was abolished in keratino-
cytes expressing 18E2. In contrast, occupancy of c-Jun and
p65, both undetectable in proliferating cells, was dramatically
increased for c-Jun at regions 3 and 4 and p65 at region 3.
Thus, JunB and JunD likely function as repressors or support
only a low level of MMP-9 expression in the proliferating state
and upon keratinocyte differentiation are replaced by c-Jun acti-
vator acting specifically through promoter-proximal AP-1 sites
centered at 76 and 533, correlating with the differentiation-
enhanced MMP-9 RNA level (Figures 6B and 6G).
Differentiation-induced p65 binding to the NF-kB site in region
3 was further stimulated by 18E2, but not 11E2, which could be
abolished by DC-1 treatment (Figure 7H) without altering the p65
protein level (Figure S6A). Because c-Jun binding to AP-1 sites in
regions 3 and 4 in the differentiation state was unaltered by E2
(Figure 7G), it is not surprising that DC-1 did not affect c-Jun
binding to these two cognate AP-1 sites inMMP-9 (Figure S6B),
confirming the specificity and selectivity of DC-1 in targeting
pNPS-dependent function of BRD4.
Combinatorial Regulation ofMMP-9 Promoter Activity
by BRD4-Regulated AP-1 and NF-kB Recruitment and
18E2-Enhanced NF-kB Activity
To examine whether differentiation-induced p65 binding to its
cognate NF-kB site in MMP-9 is triggered by nuclear transloca-
tion, we performed immunofluorescence in the three Ker-CT
lines in proliferating or differentiating states. Indeed, p65 was
found in the cytoplasm of all three proliferating cell lines and
rapidly moved to the nucleus upon differentiation (Figure S6C).
This movement was prevented by BMS-345541, a compoundted MMP-9 RNA level in differentiating Ker-CT cells.
entiating Ker-CT-derived cells by reducing BRD4 phosphorylation.
ximal region in proliferating and differentiating Ker-CT-derived keratinocytes.
roximal AP-1 site) and (F) BRD4 binding to regions 1–6 of theMMP-9 promoter-
inocytes expressing 11E2 or 18E2 in proliferation or differentiation states.
eMMP-9 promoter-proximal region in proliferating and differentiating Ker-CT-
imal region in DC-1-treated or control peptoid-treated Ker-CT-derived kerati-
MS-345541 or an AKT inhibitor.
, AP-1, and NF-kB recruitment in proliferation and differentiation states.
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that blocks IKK-mediated phosphorylation and degradation of
IkB (Burke et al., 2003) without affecting the p65 protein level
and the phosphorylation and protein level of BRD4 (Figure S6D).
In contrast, differentiation-induced c-Jun binding to MMP-9 is
caused primarily by phosphorylation of S73 and S63 in c-Jun
and enhanced protein stability (Loesch et al., 2010), which also
occurs in an E2-independent manner (Figure S6E) and is unal-
tered by BMS-345541 treatment (Figure S6D, second row).
This finding highlights two distinct mechanisms for converting
latent transcription factors to their active forms in regulating
MMP-9 promoter activity. Although the effect of E2 is not on
p65 translocation and c-Jun phosphorylation, 18E2 clearly po-
tentiates NF-kB-upregulatedMMP-9 promoter activity, because
treatment of differentiating keratinocytes with BMS-345541, but
not an AKT inhibitor, significantly reduced the 18E2-stimulated
MMP-9 RNA level to that sustained by 11E2 (Figure 7I).
BRD4 has no effect on differentiation-induced c-Jun activation
by phosphorylation (Figure S7A) and p65 activation by nuclear
translocation (Figure S7B). However, we observe that BRD4 is
essential for stable promoter-proximal occupancy of p65 and
Jun family proteins to MMP-9, because treatment of JQ1(+)
significantly reduced binding of these transcription factors to
their cognate DNA sites (Figure S7C), regardless of cells being
in a transcription-poised or transcription-activated state.
The requirement of BRD4 for AP-1 binding to the promoter re-
gion is mediated by direct interaction between BRD4 and each
component of the AP-1 family proteins, including c-Jun, JunB,
c-Fos, FosB, Fra-1, and Fra-2 and except JunD (Figure S7D).
When dimeric AP-1 complexes were formed between Jun and
Fos family members (Wang et al., 2011), all analyzed recombi-
nant AP-1 dimers, including JunD-containing complexes,
interact efficiently with purified BRD4 protein (Figure S7E).
Most AP-1 members, except FosB, did not interact individually
with CK2-phosphorylated NPS, distinct from the p50 and p65
members of NF-kB that could interact independently with
pNPS (Figure S7F).
Together with the ability of BRD4 to bind directly to p65 (Huang
et al., 2009) and to different types of E2 proteins (Muller et al.,
2012), it becomes clear that BRD4, being an interacting core,
facilitates viral E2 and cellular AP-1 and NF-kB proteins to
combinatorially regulate MMP-9 gene transcription via direct
DNA contact, as well as indirect protein anchoring in both prolif-
erating and differentiating keratinocytes (Figure 7J). The switch
from pNPS-dependent 18E2 recruitment in proliferating cells to
18E2- and pNPS-dependent NF-kB recruitment in differentiating
cells highlights the elegance of the phospho-BRD4-mediated
protein partner switch and transcription reprogramming from
the initial assembly of poised factors to the formation of a tran-
scriptionally active enhanceosome complex occurring during
cell identity shift.
DISCUSSION
BRD4 is a promising therapeutic target for a range of hematopoi-
etic cancers and solid tumors. Several small molecules can
block BRD4 binding to key regulatory regions controlling can-
cer-driver gene expression. These BET bromodomain-targeting
compounds, although effective and highly selective for BET fam-1746 Cell Reports 16, 1733–1748, August 9, 2016ily proteins, nevertheless pose potential issues for long-term
treatments that inevitably elicit side effects because of inhibition
of normal gene function critical for cell growth and differentiation.
In this study, we unravel a crucial role of BRD4 in modulating
HPV E2-regulated viral gene transcription and cellular MMP-9
expression. Our findings reveal that phosphorylation triggers a
switch within BRD4 that controls recruitment and functional
selectivity between E2 proteins encoded by cancer-associated
high-risk HPVs and non-cancer-related low-risk HPVs. This
phospho-BRD4-modulated activity also supports HPV ori-
dependent replication activity, potentiates high-risk E2-regu-
lated MMP-9 expression, and regulates combinatorial E2-NF-
kB action in controlling MMP-9 gene transcription in differenti-
ating keratinocytes. Compounds targeting this phospho-BRD4
region, such as DC-1, prove effective and highly selective in in-
hibiting high-risk E2-specific function without affecting general
activity common to every type of E2, providing a proof of concept
for future development of non-bromodomain-based BET inhibi-
tors that are more selective in target gene inhibition.
In mapping E2-interacting domains in BRD4, we identified two
internal regions (PDID andBID) that exhibit target selectivity in E2
interaction. PDID spans BD2 and a cluster of CK2 phosphoryla-
tion sites (NPS). These CK2 sites had been shown previously to
control the open or closed configuration of BD2 in binding to
acetylated chromatin and masking or unmasking of the posi-
tively charged BID for interacting with p53 (Wu et al., 2013) and
every type of E2 as reported here. Protein-protein contact may
not necessarily lead to active transcription, because only phos-
pho-PDID-recruited p53 is active in target gene regulation,
whereas BID-associated p53 is inactive in DNA binding (Wu
et al., 2013). This is similarly reflected in poised binding of
11E2 and 18E2 to their direct E2 target site in region 2 and in
expanded recruitment, via BRD4 association with AP-1 family
members, to the AP-1 site-containing regions 1, 3, and 4 of
MMP-9 gene in proliferating keratinocytes (Figure 7D), which
does not contribute to the transcriptional readout ofMMP-9 (Fig-
ures 6B and 6G). Robust transcription occurs upon cytokine-
induced differentiation when active NF-kB becomes available
in the nucleus for binding to its cognate site in region 3, potenti-
ated by high-risk 18E2, and is accompanied by dissociation of
JunB/JunD binding to regions 1, 3, and 4 and association of
c-Jun binding to regions 3 and 4 (Figure 7G). The dynamics
of factor switches and reorganization of viral and cellular tran-
scription factors in regulating MMP-9 gene transcription during
conversion from proliferating to differentiation states elegantly
illustrate the intricacy of combinatorial regulation of eukaryotic
transcription coordinated by the epigenetic regulator BRD4 via
a phosphorylation-controlled mechanism, which likely extends
to several hundred other DC-1-regulated differentiation-specific
genes identified by exome sequencing (S.-Y.W., Y.J. Kim, T.H.
Kim, and C.-M.C., unpublished data), learning and memory
(Korb et al., 2015), and the cancer cell progression seen in triple
negative breast cancer (Shu et al., 2016).
The existence of a second universal E2-interacting domain
(BID) in BRD4 typically masked in vivo by phosphorylation of
an adjacent regulatory domain (PDID), together with the previ-
ously characterized CTM that is surface-exposed and uniquely
present in BRD4 among the ubiquitously expressed BET family
proteins, highlights a specific requirement of FL (long-form)
BRD4 (but not CTM-lacking BRD2, BRD3, and BRD4-S) for
E2-regulated HPV and cellular gene transcription. It further high-
lights a two-arm chelating mechanism unleashed upon dephos-
phorylation or factor-induced conformational change for high-
risk E2 to switch contact with BRD4 from phospho-PDID to
BID and for low-risk E2 to capture a newly exposed surface.
This surface engages in a distinct type of functional regulation,
presumably via context-dependent partner switch. Our findings
indicate that phosphorylation and combinatorial regulation play
key roles in the control of cellular and viral transcription by BRD4.
EXPERIMENTAL PROCEDURES
Plasmids and Protein Purification
Procedures for constructing protein expression plasmids (Table S1) and pro-
tein purification have been previously described (Thomas and Chiang, 2005;
Wu and Chiang, 2009; Wang et al., 2011) and are detailed in Supplemental
Information.
Peptoid Synthesis
Synthesis of DC-1, DC-2, and control peptoids is detailed in Supplemental
Information.
Cell Lines and Lentivirus
Stable lines derived from HeLa/16E6/16E7 and C-33A/18LCR (Smith et al.,
2010) for expressing 16E2, BE2, or vector alone and from Ker-CT (Ramirez
et al., 2003) for expressing 11E2, 18E2, or vector alone were generated as
described in Supplemental Information, along with details for medium, trans-
fection, and production of E2 lentivirus.
GST Pull-Down and CoIP
Protein-protein interactions conducted with GST pull-down or coIP and
analyzed by immunoblotting are described in Supplemental Information.
BiFC Assay
Detection of E2-BRD4 interaction in vivo by BiFC live-cell imaging (Wu et al.,
2013) with HeLa and C-33A cells is described in Supplemental Information.
Kinase or Chemical Inhibition and Phosphorylation Altering Assay
CIP and CK2 treatment of purified BRD4 proteins has been previously
described (Wu et al., 2013), with compound addition and determination of
the dissociation constant (Kd) and IC50 for BRD4 binding to E2 or acetylated
chromatin described in Supplemental Information.
Kinase Inhibitor Assay
Pharmacological inhibitors against CK2 (TBB), PP2A (PTZ), NF-kB (BMS-
345541), and AKT (1L6-hydroxymethyl-chiro-inositol-2-(R)-2-O-methyl-3-O-
octadecyl-sn-glycerocarbonate) were added to cells and analyzed for localiza-
tion of p65 by immunofluorescence staining, for the phosphorylation status of
c-Jun and BRD4 by immunoblotting, and forMMP-9 RNA levels by qRT-PCR
as described in Supplemental Information.
Transient Replication and Replication Foci Assay
Transient HPV replication assay was performed in C-33A cells by transfection
with HPV-16 E1, 16E2, and HPV-16 ori-containing plasmids, together with
wild-type BRD4, 7A, or vector construct, and analyzed by qPCR. Confocal im-
aging of E2-BRD4 foci in similarly transfected C-33A cells is also detailed in
Supplemental Information.
Cell Proliferation and Transwell Migration Assay
Proliferation of Ker-CT-derived cells analyzed with Calcein AM fluorescent dye
and migration of HT1080 cells monitored by Transwell with subsequent Cal-
cein AM labeling are detailed in Supplemental Information.Gel Zymography
Analysis of secreted MMP-9 gelatinase activity in Ker-CT-derived cells was
conducted by in-gel zymography following SDS-PAGE (see Supplemental
Information).
ChIP, qRT-PCR, and siRNA Knockdown
ChIP assay, qRT-PCR, and siRNA knockdown were performed as previously
described (Wu et al., 2013) using primer sequences for specific gene loci (Ta-
ble S2) and for BET siRNA knockdown (Table S3), with sources of antibodies
(Table S4) and procedures detailed in Supplemental Information.
Structure Analysis and Sequence Alignment of E2 DNA-Binding
Domains
Structures of 16E2 DBD (Research Collaboratory for Structural Bioinformatics
PDB: 1ZZF) and 18E2 DBD in complex with DNA (PDB: 1JJ4; Kim et al., 2000)
were analyzed by PyMOL as detailed in Supplemental Information.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and four tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2016.07.001.
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